Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Qualigen Therapeutics Inc (NASDAQ: QLGN) closed the day trading at $3.12 down -21.42% from the previous closing price of $3.97. In other words, the price has decreased by -$21.42 from its previous closing price. On the day, 1.15 million shares were traded. QLGN stock price reached its highest trading level at $4.04 during the session, while it also had its lowest trading level at $2.99.
Ratios:
For a better understanding of QLGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.52 and its Current Ratio is at 0.52.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, QLGN now has a Market Capitalization of 2297664 and an Enterprise Value of 2426547.
Stock Price History:
The Beta on a monthly basis for QLGN is -0.67, which has changed by -0.84904945 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, QLGN has reached a high of $29.43, while it has fallen to a 52-week low of $3.34. The 50-Day Moving Average of the stock is -25.70%, while the 200-Day Moving Average is calculated to be -65.81%.
Shares Statistics:
Over the past 3-months, QLGN traded about 59.93K shares per day on average, while over the past 10 days, QLGN traded about 53330 shares per day. A total of 0.74M shares are outstanding, with a floating share count of 0.69M. Insiders hold about 6.96% of the company’s shares, while institutions hold 1.71% stake in the company. Shares short for QLGN as of 1730332800 were 15588 with a Short Ratio of 1.16, compared to 1727654400 on 2179. Therefore, it implies a Short% of Shares Outstanding of 15588 and a Short% of Float of 2.8499998.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.